{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-032502","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2025-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.575752+00:00","generated_at":"2026-05-17T10:09:53.673846+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rocket Pharma CFO resigns; General Counsel named interim CFO","bullets":["Aaron Ondrey resigned as CFO effective September 5, 2025 to pursue other opportunities.","Martin Wilson, General Counsel and Chief Corporate Officer, appointed interim Principal Financial Officer effective September 8, 2025.","Wilson joined Rocket in November 2021; has nearly 20 years of life sciences legal and executive experience.","No family relationships or transactions with the company beyond compensation for current roles."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-032502","json":"https://secwatch.observer/filing/0001140361-25-032502.json","markdown":"https://secwatch.observer/filing/0001140361-25-032502.md","text":"https://secwatch.observer/filing/0001140361-25-032502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125032502/0001140361-25-032502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125032502/ef20054457_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:09:53.673846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}